TLPH (Talphera, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TLPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Marina Bozilenko | Director | A | — | — |
| 2026-06-24 | Joseph Todisco | Director | A | — | — |
| 2026-06-24 | MARK A WAN | Director | A | — | — |
| 2026-06-24 | Jill Marie Broadfoot | Director | A | — | — |
| 2026-06-24 | STEPHEN J HOFFMAN | Director | A | — | — |
| 2026-06-24 | ABHINAV JAIN | Director | A | — | — |
| 2026-06-24 | ADRIAN ADAMS | Director | A | — | — |
| 2026-05-21 | Shakil Aslam | Chief Medical Officer | F | — | — |
| 2026-04-03 | Shakil Aslam | Chief Medical Officer | F | — | — |
| 2026-04-03 | RAFFI ASADORIAN | Chief Financial Officer | F | — | — |
| 2026-04-03 | Badri N Dasu | Chief Engineering Officer | F | — | — |
| 2026-04-03 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-03-25 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2026-03-17 | Wilmot B. Harkey | 10%+ Owner | A | — | — |
| 2026-02-20 | RAFFI ASADORIAN | Chief Financial Officer | MIXED | — | — |
| 2026-02-20 | Shakil Aslam | Chief Medical Officer | Buy | — | — |
| 2026-02-20 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-02-20 | Badri N Dasu | Chief Engineering Officer | MIXED | — | — |
| 2025-10-24 | ADRIAN ADAMS | Director | A | — | — |
| 2025-10-24 | ABHINAV JAIN | Director | A | — | — |
| 2025-10-24 | Jill Marie Broadfoot | Director | A | — | — |
| 2025-10-24 | Marina Bozilenko | Director | A | — | — |
| 2025-10-24 | MARK A WAN | Director | A | — | — |
| 2025-10-24 | STEPHEN J HOFFMAN | Director | A | — | — |
| 2025-10-16 | Joseph Todisco | Director | A | — | — |
| 2025-05-21 | Shakil Aslam | Chief Medical Officer | F | — | — |
| 2025-04-03 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-04-03 | Badri N Dasu | Chief Engineering Officer | A | — | — |
| 2025-04-03 | RAFFI ASADORIAN | Chief Financial Officer | A | — | — |
| 2025-04-03 | Shakil Aslam | Chief Medical Officer | A | — | — |
| 2025-04-02 | Daniel Mack | 10%+ Owner | A | — | — |
| 2025-02-26 | Shakil Aslam | Chief Medical Officer | Buy | — | — |
| 2025-02-18 | RAFFI ASADORIAN | Chief Financial Officer | F | — | — |
| 2025-02-18 | Badri N Dasu | Chief Engineering Officer | F | — | — |
| 2025-02-18 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-02-12 | RAFFI ASADORIAN | Chief Financial Officer | F | — | — |
| 2025-02-12 | Badri N Dasu | Chief Engineering Officer | F | — | — |
| 2025-02-12 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2024-12-06 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2024-12-02 | RAFFI ASADORIAN | Chief Financial Officer | Sell | — | — |
| 2024-12-02 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2024-09-03 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2024-06-24 | MARK A WAN | Director | A | — | — |
| 2024-06-24 | ADRIAN ADAMS | Director | A | — | — |
| 2024-06-24 | ABHINAV JAIN | Director | A | — | — |
| 2024-06-24 | STEPHEN J HOFFMAN | Director | A | — | — |
| 2024-06-24 | Marina Bozilenko | Director | A | — | — |
| 2024-06-24 | Jill Marie Broadfoot | Director | A | — | — |
| 2024-06-14 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2024-03-21 | Wilmot B. Harkey | 10%+ Owner | J | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,992,519 | — |
| — | CHIEF EXECUTIVE OFFICER | 790,767 | — |
| — | Chief Financial Officer | 85,879 | — |
| — | Chief Medical Officer | 76,542 | — |
| — | Chief Engineering Officer | 71,440 | — |
| — | Chief Medical Officer | 59,149 | — |
| — | Director | 22,709 | — |
| — | Director | 14,147 | — |
| — | Director | 13,959 | — |
| — | Director | 13,959 | — |
| — | Director | 13,647 | — |
| — | Director | 12,412 | — |
| — | Director | 11,497 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TLPH quote page; the site-wide leaderboard is on the insider transactions hub.